Literature DB >> 12097172

Cleavage of an inaccessible site by the maxizyme with two independent binding arms: an alternative approach to the recruitment of RNA helicases.

Tomoko Kuwabara1, Masaki Warashina, Kazunari Taira.   

Abstract

To overcome obstacles to target site selection, we recently created a novel hybrid ribozyme that could access any chosen site by the recruitment of intracellular RNA helicases [Warashina et al. (2001) Proc. Natl. Acad. Sci. USA 98, 5572-5577; Kawasaki et al. (2002) Nat. Biotech. 20, 376-380]. We also demonstrated previously that pol III-driven maxizymes with two substrate-binding arms that were directed against two different sites within a target mRNA formed very active heterodimers in vivo [Kuwabara, et al. (2000) Trends Biotechnol. 18, 462-468; Tanabe et al. (2001) Nature 406, 473-474]. Despite the complicated dimerization process, all the maxizymes that we tested in cultured cells had greater catalytic activity than the parental ribozymes. To investigate the action of maxizymes in cells, we designed a specific maxizyme with two substrate-binding arms that was directed against endogenously expressed LTR-luciferase chimeric mRNA, where LTR refers to the long terminal repeat of HIV-1. One substrate-binding arm of the maxizyme was designed to bind to a site within HIV-1 TAR RNA that is known to form a stable stem structure that normally prevents binding of a ribozyme. The other substrate-binding arm was directed against a relatively accessible site within the luciferase gene. As expected, the conventional ribozyme failed to cleave the TAR region in vivo because of the latter's stable secondary structure. However, to our surprise, the maxizyme cleaved the TAR region within the stem with high efficiency in vivo. The enhanced cleavage in vivo by the maxizyme might have resulted from an entropically favorable, intramolecular, second binding process that occurred during the breathing of the stem structure of the target mRNA. Importantly, our data suggest that this maxizyme technology might be used as an alternative approach to the recruitment of RNA helicases in cleaving sites previously found to be inaccessible.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097172     DOI: 10.1093/oxfordjournals.jbchem.a003193

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  5 in total

1.  Maxizyme-mediated specific inhibition on mutant-type p53 in vitro.

Authors:  Xin-Juan Kong; Yu-Hu Song; Ju-Sheng Lin; Huan-Jun Huang; Nan-Xia Wang; Nan-Zhi Liu; Bin Li; You-Xin Jin
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 2.  External guide sequence technology: a path to development of novel antimicrobial therapeutics.

Authors:  Carol Davies-Sala; Alfonso Soler-Bistué; Robert A Bonomo; Angeles Zorreguieta; Marcelo E Tolmasky
Journal:  Ann N Y Acad Sci       Date:  2015-04-09       Impact factor: 5.691

3.  Inhibition of aminoglycoside 6'-N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides.

Authors:  Renee Sarno; Hongphuc Ha; Natalia Weinsetel; Marcelo E Tolmasky
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

4.  Targeting mortalin using conventional and RNA-helicase-coupled hammerhead ribozymes.

Authors:  Renu Wadhwa; Hiroshi Ando; Hiroaki Kawasaki; Kazunari Taira; Sunil C Kaul
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

5.  Effective suppression of Dengue fever virus in mosquito cell cultures using retroviral transduction of hammerhead ribozymes targeting the viral genome.

Authors:  Pruksa Nawtaisong; James Keith; Tresa Fraser; Velmurugan Balaraman; Andrey Kolokoltsov; Robert A Davey; Stephen Higgs; Ahmed Mohammed; Yupha Rongsriyam; Narumon Komalamisra; Malcolm J Fraser
Journal:  Virol J       Date:  2009-06-04       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.